Literature DB >> 9973517

Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis.

T Sparwasser1, L Hültner, E S Koch, A Luz, G B Lipford, H Wagner.   

Abstract

Bacterial DNA and the synthetic CpG-oligodeoxynucleotides (ODNs) derived thereof have attracted attention because they activate cells of the adaptive immune system (lymphocytes) and the innate immune system (APCs) in a sequence-dependent manner. Here, we addressed whether CpG-ODNs affect hemopoiesis. Challenging mice with immunostimulatory CpG-ODN sequences led to transient splenomegaly, with a maximum increase of spleen weight at day 6. The induction of splenomegaly by CpG-ODNs was sequence-specific, dose-dependent, and associated with an increase in splenic cell count, in numbers of granulocyte-macrophage CFUs (GM-CFUs), and early erythroid progenitors (burst-forming units-erythroid). The transfer of spleen cells from CpG-ODN-pretreated animals into lethally irradiated syngeneic mice yielded an increase of spleen CFUs. Furthermore, the challenge of sublethally irradiated mice with CpG-ODNs caused radioprotective effects, in that recovery of GM-CFUs and cytotoxic T cell function was enhanced. The increase in GM-CFU and CTL function correlated with an enhanced resistance to Listeria infection in irradiated mice. We conclude from these data that CpG-ODNs trigger extramedullary hemopoiesis, and that this finding could be of therapeutic relevance in myelosuppression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9973517

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  36 in total

Review 1.  Immunostimulatory DNA sequences help to eradicate intracellular pathogens.

Authors:  H Wagner; H Häcker; G B Lipford
Journal:  Springer Semin Immunopathol       Date:  2000

2.  Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression.

Authors:  J Melo-Cardenas; M Urquiza; T J Kipps; J E Castro
Journal:  Cancer Gene Ther       Date:  2012-03-09       Impact factor: 5.987

3.  CpG-ODN 2006 and human parvovirus B19 genome consensus sequences selectively inhibit growth and development of erythroid progenitor cells.

Authors:  Yong-Mei Guo; Keiko Ishii; Makoto Hirokawa; Hiroyuki Tagawa; Hideaki Ohyagi; Yoshihiro Michishita; Kumi Ubukawa; Junsuke Yamashita; Toshiaki Ohteki; Nobuyuki Onai; Kazuyoshi Kawakami; Weiguo Xiao; Kenichi Sawada
Journal:  Blood       Date:  2010-03-26       Impact factor: 22.113

4.  Preinfection treatment of resistant mice with CpG oligodeoxynucleotides renders them susceptible to friend retrovirus-induced leukemia.

Authors:  Anke R M Olbrich; Simone Schimmer; Ulf Dittmer
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

5.  Short- and long-term changes in gene expression mediated by the activation of TLR9.

Authors:  Sven Klaschik; Debra Tross; Hidekazu Shirota; Dennis M Klinman
Journal:  Mol Immunol       Date:  2009-12-14       Impact factor: 4.407

6.  CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma.

Authors:  Xian-Song Wang; Zhen Sheng; You-Bing Ruan; Yang Guang; Mu-Lan Yang
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

7.  A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma.

Authors:  Xiaoming Yao; Ji-Fan Hu; Mark Daniels; Hadas Shiran; Xiangjun Zhou; Huifan Yan; Hongqi Lu; Zhilan Zeng; Qingxue Wang; Tao Li; Andrew R Hoffman
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

8.  Murine J774 macrophages recognize LPS/IFN-g, non-CpG DNA or two-CpG DNA-containing sequences as immunologically distinct.

Authors:  Lynn Crosby; Warren Casey; Kevin Morgan; Hong Ni; Lawrence Yoon; Marilyn Easton; Mary Misukonis; Gary Burleson; Dipak K Ghosh
Journal:  Nitric Oxide       Date:  2010-01-25       Impact factor: 4.427

9.  Identification of immunologic and pathologic parameters of death versus survival in respiratory tularemia.

Authors:  Damiana Chiavolini; Joseph Alroy; Carol A King; Peter Jorth; Susan Weir; Guillermo Madico; John R Murphy; Lee M Wetzler
Journal:  Infect Immun       Date:  2007-11-19       Impact factor: 3.441

10.  Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Camila Santucci; Brian Tran; Robert Langer; Gregory T Zugates; Daniel G Anderson; Richard S Kornbluth
Journal:  PLoS One       Date:  2009-10-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.